Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates
A number of computational approaches are being proposed for an early optimization of ADME (absorption, distribution, metabolism and excretion) properties to increase the success rate in drug discovery. The present study describes the development of an in silico model able to estimate, from the three-dimensional structure of a molecule, the stability of a compound with respect to the human cytochrome P450 (CYP) 3A4 enzyme activity. Stability data were obtained by measuring the amount of unchanged compound remaining after a standardized incubation with human cDNA-expressed CYP3A4. The computational method transforms the three-dimensional molecular interaction fields (MIFs) generated from the molecular structure into descriptors (VolSurf and Almond procedures). The descriptors were correlated to the experimental metabolic stability classes by a partial least squares discriminant procedure. The model was trained using a set of 1800 compounds from the Pharmacia collection and was validated using two test sets: the first one including 825 compounds from the Pharmacia collection and the second one consisting of 20 known drugs. This model correctly predicted 75% of the first and 85% of the second test set and showed a precision above 86% to correctly select metabolically stable compounds. The model appears a valuable tool in the design of virtual libraries to bias the selection toward more stable compounds.
Abbreviations: ADME – absorption, distribution, metabolism and excretion; CYP – cytochrome P450; MIFs – molecular interaction fields; HTS – high throughput screening; DDI – drug-drug interactions; 3D – three-dimensional; PCA – principal components analysis; CPCA – consensus principal components analysis; PLS – partial least squares; PLSD – partial least squares discriminant; GRIND – grid independent descriptors; GRID – software originally created and developed by Professor Peter Goodford.
Unable to display preview. Download preview PDF.
- 1.Clark, D.E. and Pickett, S.D., Drug Discov. Today, 5 (2000) 49.Google Scholar
- 3.van de Waterbeemd, H., Curr. Opin. Drug Discov. Dev., 5 (2002) 33.Google Scholar
- 7.Testa, B., In Wolff, M. (Ed) Drug Metabolism, in Burger's Medicinal Chemistry and Drug Discovery. Principles and Practice, Vol. 1. John Wiley & Son, New York, 1994, pp. 129–180.Google Scholar
- 8.Bertrand, M., Jackson, P. and Walther, P., Eur. J. Pharm. Sci. 11 (2 Suppl) (2000) S61.Google Scholar
- 11.Thummel, K.E. and Shen, D.D., In Hardman, J.G., Limbird, L.E., Molinoff, P.B. and Gilman, A.G. (Eds), Appendix II. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. In Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill, New York, 2001, pp. 1917–2023.Google Scholar
- 12.Cruciani, G., Crivori, P., Carrupt, P-A. and Testa, B., Theochem,503 (2000) 17.Google Scholar
- 16.CORINA. Molecular Networks, GmbH, Computerchemie, Erlangen, Germany, 1998.Google Scholar
- 17.VolSurf v.3.0, Molecular Discovery Ltd., Oxford, UK, 2002.Google Scholar
- 18.Almond v.3.0, Multivariate Infometric Analysis S.r.l., Perugia, Italy, 2002.Google Scholar
- 19.Wold, S., Esbensen, K. and Geladi, P., Chemom. Intell. Lab. Syst., 2 (1987) 37.Google Scholar
- 21.Dunn, W.J. and Wold, S., Pattern Recognition Techniques in drug design. In Hansch, C., Sammes, P.G. and Taylor, J.B. (Eds), Comprehensive Medicinal Chemistry, Vol. 4, Pergamon Press, Oxford, UK, 1990, pp. 691–714.Google Scholar
- 22.GOLPE 4.5, Multivariate Infometric Analysis S.r.l., Perugia, Italy, 2002.Google Scholar
- 23.GRID v. 20, Molecular Discovery Ltd., Oxford, UK, 2002.Google Scholar
- 25.Wold, S., Technometrics, 20 (1979) 379.Google Scholar
- 26.Wold, S., Albano, C., Dunn, W. J. III, Edlund, U., Esbensen, K., Geladi, P., Helberg, S., Johansson, E., Lindberg, W. and Sjostrom, M., Multivariate data analysis in chemistry. In Kowalsky, B.R. (Ed), Chemometrics Mathematics and Statistics in Chemistry. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1983, pp. 17–96.Google Scholar
- 27.Cruciani, G., Pastor, M. and Guba, W., Eur. J. Pharm. Sci., 11(Suppl. 2) (2000) S29.Google Scholar
- 32.Guengerich, F.P., Annu. Rev. Pharmaco. Toxicol., 39 (1999)1.Google Scholar
- 35.Smith, D.A., Ackland, M.J. and Jones, B.C., Drug Discov. Today, 2(10) (1997) 406.Google Scholar
- 36.Smith, D.A., Ackland, M.J. and Jones, B.C., Drug Discov. Today, 2(11) (1997) 479.Google Scholar